New drugs or alternative therapy to blurring the symptoms of fibromyalgia—a patent review. (3rd October 2017)

• Record Type: Journal Article
• Authors: Oliveira, Marlange A.; Guimarães, Adriana G.; Araújo, Adriano A. S.; Quintans-Júnior, Lucindo J.; Quintans, Jullyana S. S.
• Is Part Of: Expert opinion on therapeutic patents. Volume 27:Number 10(2017:Oct.)
• Page Start: 1147
• Page End: 1157
• Publication Date: 2017-10-03
• Subjects: Fibromyalgia -- therapeutic patents -- exploration technology -- drugs; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2017.1349105
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : Fibromyalgia (FM) is a musculoskeletal condition characterized by chronic widespread pain, tenderness and often accompanied by other comorbid conditions such as depression, anxiety, chronic fatigue, among others. Now, we aimed to survey the recent patents describing new drugs or alternative therapy for FM. Areas covered : This review covers the therapeutic patents published between 2010 and 2017 from specialized search databases (WIPO, DERWENT, INPI, ESPANET and USPTO) that report the discovery of new drugs or pharmacologic alternative for the treatment of FM. Expert opinion : New therapeutic substances have been proposed in the last seven years. At least as it has been found in our survey, most are still in the pre-clinical phase of the study, and its clinical applicability is unclear. However, other therapeutic approaches were found in patents such as well-established drugs in the market in combination or drug repositioning that combines the 'new analgesic' effects with the old side effects. Hence, it is a safe approach for pharmaceutical market, but poorer to patients who need a radical innovation. So, there is the emerging need for further studies on the safety and efficacy of such therapeutic measures and the search for improvement of side effects, as well as the development of new drugs that are unorthodox for different FM symptoms.